Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Cubist Discloses FCPA Probe

Jaclyn Jaeger | August 13, 2014

Cubist Pharmaceuticals disclosed this week in a regulatory filing with the Securities and Exchange Commission that it is under investigation by the SEC and Department of Justice for potential violations of the Foreign Corrupt Practices Act.

In a Form 8-K, dated Aug. 11, Cubist said the FCPA allegations concern "a potentially improper payment to a research laboratory" and an "attempted share grant” in 2011 by Optimer Pharmaceuticals, a biopharmaceutical company that Cubist acquired last year.

Cubist did not provide any further details on the investigation. In March 2013, however, the company disclosed in a regulatory filing that the company’s CEO and its chief compliance officer resigned at the request of independent board members after a year-long internal investigation...

Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.